Deepak Bhatt, MD, Discusses Treatment that Reduces Cardiovascular Events in Patients with Compromised Renal Function

By Rob Dillard - Last Updated: November 18, 2020

Deepak Bhatt, MD, sat down with DocWire News to discuss a study that found that VASCEPA® (icosapent ethyl), significantly reduced cardiovascular (CV) events in patients with compromised renal function.

Post Tags:Cardiology Videos kidney function

World Hypertension Day: What Cardiologists Need to Know

Payal Kohli, MD, FACCHypertension | May 16, 2025

Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter.

TAVR Valve Face-Off Reveals Tradeoffs in Safety and Function

Amit Goyal, MDCardioNerds | May 14, 2025

NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes

Brisk Walking Linked to Lower Risk of Cardiac Arrhythmias

Pam BeilerPreventive Cardiology | May 13, 2025

Walking at a brisk pace may significantly reduce the risk of heart rhythm disorders, new UK Biobank research shows.

Genetic Testing May Predict Future Cardiomyopathy, Heart Failure in Patients With Atrial Fibrillation

Jordana JampelAtrial Fibrillation | May 13, 2025

The presence of a CMP-PLP variant was linked to a 1.6-fold increased risk for cardiomyopathy or heart failure.

Hypertension Death Risk Falls Sharply With Risk Factor Control

Joy ManningHypertension | May 12, 2025

Controlling multiple health risks may eliminate premature death risk in people with hypertension, a major study finds.

Deepak Bhatt, MD, Discusses Treatment that Reduces Cardiovascular Events in Patients with Compromised Renal Function

Related Posts